Мақаланы E-mail арқылы жіберу Better understanding of phosphoinositide 3-kinase (PI3K) pathways in vasculature: Towards precision therapy targeting angiogenesis and tumor blood supply
- Авторлар: Tsvetkov D.1, Shymanets A.2, Huang Y.3, Bucher K.2, Piekorz R.4, Hirsch E.5, Beer-Hammer S.2, Harteneck C.2, Gollasch M.1, Nürnberg B.2
-
Мекемелер:
- Experimental and Clinical Research Center, Section Nephrology/Intensive Care
- Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
- School of Biomedical Sciences
- Institute for Biochemistry and Molecular Biology II
- Molecular Biotechnology Centre, Department of Molecular Biotechnology and Health Sciences
- Шығарылым: Том 81, № 7 (2016)
- Беттер: 691-699
- Бөлім: Article
- URL: https://journals.rcsi.science/0006-2979/article/view/150936
- DOI: https://doi.org/10.1134/S0006297916070051
- ID: 150936
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
The intracellular PI3K-AKT-mTOR pathway is involved in regulation of numerous important cell processes including cell growth, differentiation, and metabolism. The PI3Kα isoform has received particular attention as a novel molecular target in gene therapy, since this isoform plays critical roles in tumor progression and tumor blood flow and angiogenesis. However, the role of PI3Kα and other class I isoforms, i.e. PI3Kβ, γ, δ, in the regulation of vascular tone and regional blood flow are largely unknown. We used novel isoform-specific PI3K inhibitors and mice deficient in both PI3Kγ and PI3Kδ (Pik3cg–/–/Pik3cd–/–) to define the putative contribution of PI3K isoform(s) to arterial vasoconstriction. Wire myography was used to measure isometric contractions of isolated murine mesenteric arterial rings. Phenylephrine-dependent contractions were inhibited by the pan PI3K inhibitors wortmannin (100 nM) and LY294002 (10 μM). These vasoconstrictions were also inhibited by the PI3Kα isoform inhibitors A66 (10 μM) and PI-103 (1 μM), but not by the PI3Kβ isoform inhibitor TGX 221 (100 nM). Pik3cg–/–/Pik3cd–/–-arteries showed normal vasoconstriction. We conclude that PI3Kα is an important downstream element in vasoconstrictor GPCR signaling, which contributes to arterial vasocontraction via α1-adrenergic receptors. Our results highlight a regulatory role of PI3Kα in the cardiovascular system, which widens the spectrum of gene therapy approaches targeting PI3Kα in cancer cells and tumor angiogenesis and regional blood flow.
Негізгі сөздер
Авторлар туралы
D. Tsvetkov
Experimental and Clinical Research Center, Section Nephrology/Intensive Care
Email: maik.gollasch@charite.de
Германия, Berlin, 13125
A. Shymanets
Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
Email: maik.gollasch@charite.de
Германия, Tübingen, 72074
Yu Huang
School of Biomedical Sciences
Email: maik.gollasch@charite.de
ҚХР, 223A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, Hong Kong
K. Bucher
Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
Email: maik.gollasch@charite.de
Германия, Tübingen, 72074
R. Piekorz
Institute for Biochemistry and Molecular Biology II
Email: maik.gollasch@charite.de
Германия, Düsseldorf, 40225
E. Hirsch
Molecular Biotechnology Centre, Department of Molecular Biotechnology and Health Sciences
Email: maik.gollasch@charite.de
Италия, Turin, 10126
S. Beer-Hammer
Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
Email: maik.gollasch@charite.de
Германия, Tübingen, 72074
C. Harteneck
Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
Email: maik.gollasch@charite.de
Германия, Tübingen, 72074
M. Gollasch
Experimental and Clinical Research Center, Section Nephrology/Intensive Care
Хат алмасуға жауапты Автор.
Email: maik.gollasch@charite.de
Германия, Berlin, 13125
B. Nürnberg
Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Pharmacology and Experimental Therapy
Email: maik.gollasch@charite.de
Германия, Tübingen, 72074
Қосымша файлдар
